BioNeutral
Group, Inc. (
Dr. Dorothy Canter is a senior professional biophysicist at the Johns Hopkins University Applied Physics Laboratory. During the past two years, she has been actively engaged in activities for the protection of critical infrastructure. In particular, she was a key organizer for the June 2005 Airport Preparedness Workshop and has worked on airport protection issues since then. She served on the organizing committee for the two environmental sampling conferences on biothreat agents and contributed a chapter to the book on the first conference. Dr. Canter has published widely in the peer-reviewed literature and given numerous lectures at national and international meetings on anthrax decontamination, residual risk and preparedness activities.
From November 2001 through June 2005, she served as the Chief Scientist for Bioterrorism Issues in the Office of Solid Waste and Emergency Response (OSWER) of the US Environmental Protection Agency (EPA). She participated in the overall cleanup process for the Capitol Hill Anthrax Site in 2001. Based upon the lessons learned from that cleanup, she contributed actively to the implementation of more stringent criteria for future cleanups and served as co-chair of the Technical Working Groups for the remediation of two facilities needing fumigations. Prior to serving as the Chief Scientist for Bioterrorism Issues, Dr. Canter served as OSWER’s Science Policy Advisor for 15 years. She was an expert on incineration risk assessment, toxicity of environmental chemicals and peer review of highly controversial scientific issues. Through her tenure with the EPA, Dr. Canter developed unique expertise in biothreat agent decontamination.
Dr. Canter has also served for ten years as Assistant to the Director of National Toxicology Program. She also worked for four years at the Consumer Product Safety Commission, evaluating the toxic effects of chemicals in consumer products. Dr. Canter received both a B.S. in mathematics and a Ph.D. in biophysics from The George Washington University.
“We welcome Dr. Canter to BioNeutral Group. Her expertise in Bioterrorism and Homeland Security issues will certainly play a vital role in opening the communication with officials within Homeland Security with regards to the capability of our Ygiene™ and Ogiene™ technology to revolutionize the methods and means of acting upon future biothreats,” said President and CEO of BioNeutral Group, Inc., Stephen J. Browand.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a novel combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.
More information about the Company may be found at www.bioneutralgroup.com
Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.